Andrea Noya-Mourullo

Dr. Andrea Noya-Mourullo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Andrea Noya-MourulloAndrea Noya-Mourullo
Andrea Noya-Mourullo
AMAlejandro Martín-Parada
Alejandro Martín-Parada
APAlberto Palacios-Hernández
Alberto Palacios-Hernández
PEPablo Eguiluz-Lumbreras
Pablo Eguiluz-Lumbreras
ÓHÓscar Heredero-Zorzo
Óscar Heredero-Zorzo
MLMaría-Fernanda Lorenzo-Gómez
María-Fernanda Lorenzo-Gómez
Introduction: The protocol for deceased donor kidney transplants has been standardised. The procedure for a living donor has peculiarities derived from the differences in the graft. When a living kidney donor program is implemented, changes occur in both the profile of the kidney transplant candidate and in the postoperative treatments. Aims: To discover whether a living donor program influences the functional outcomes of kidney grafts in a longstanding classical deceased donor kidney transplant program and to identify the factors associated with transplant outcomes. Methods: Retrospective observational multicentre study. Sample: Kidney transplant patients in two urology referral centres for renal transplant in Spain between 1994 and 2019. Groups: TV (living transplant): patients given kidney transplants from living donors (n = 150); TCpre11 (deceased transplant previous to 2011): patients given kidney transplants from deceased donors before the living donor program was implemented (n = 650); and TCpost11 (deceased transplant after 2011): patients given kidney transplants from deceased donors after the living donor program was implemented (n = 500). Results: Mean age was 55.75 years (18–80 years), higher in TCpre11. There were 493 female patients (37.92%) and 1007 male patients (62.08%). Mean body mass index (BMI) was 26.69 kg/m2 (17.50–42.78 kg/m2), higher in TCpre11. Mean ischemia time was 17.97 h (6–29 h), higher in TCpost11. Median duration of urethral catheter: 8 days (6–98 days), higher in TCpost11. Median duration of double-J ureteral stent: 58 days (24–180 days), higher in TCpost11. Pretransplant UTIs: 17.77%, higher in TCpre11 (25.69%) than in TV (12%), higher in TV (12%) than TCpost11 (9.2%), and higher in TCpre11 (25.69%) than TCpost11 (9.2%). Acute renal rejection in 9.33% of TV, 14.77% of TCpre11, and 9.8% of TCpost11. Multivariate analysis: TCpost11 featured higher BMI, more smoking, and chronic renal failure progression time. Lower use of nonantibiotic prophylaxis to prevent recurrent urinary tract infections, increased duration of urethral catheters due to obstructive problems, and favoured deterioration of kidney function was observed in the deceased donor program. The living donor (LD) program had a strong influence on deceased donor transplants in the prelysis phase. Implementation of a LD program was associated with a decrease in the likelihood of acute rejection in TCpost11 and an increase in the tendency towards normal kidney function. Conclusions: Implementing living donor transplant programs affects functional outcomes in deceased donor transplants, reducing the probability of acute rejection and increasing the tendency towards normal kidney function. Preventing recurrent urinary tract infections with measures other than antibiotics, smoking cessation, delaying the removal of the double-J stent from the graft, and pre-emptive transplant (transplant prior to dialysis) are associated with improved renal function of the graft.

23 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FBFrancesco Barletta
Francesco Barletta
NFNicola Frego
Nicola Frego
MAMario De Angelis
Mario De Angelis
SRStefano Resca
Stefano Resca
MTMarco Ticonosco
Marco Ticonosco
GNGeert De Naeyer
Geert De Naeyer
Introduction: Available guidelines recommend performing nephron-sparing surgery in selected renal cell carcinoma (RCC) patients. Many studies provided robot-assisted partial nephrectomy (RAPN) functional and oncological outcomes, with most of these including a wide timespan and a number of surgeons with different experiences, which might lead to the heterogeneity of the results. In this study, we aim to provide a contemporary report of RAPN patient outcomes performed at two referral centers by experienced surgeons. Materials and Methods: Overall, 333 RAPN patients treated at two European referral centers between 2019 and 2021 were identified. Continuous and categorical variables were reported using medians and proportions. Multi-variable logistic regression (MLR) models were fitted to test predictors of off-clamp technique use and trifecta achievement. Results: The median age was 65 (IQR: 57–73) years. The clinical stage distribution was as follows: 224 (67%) cT1a vs. 89 (26%) cT1b vs. 20 cT2 (7%). The median warm ischemia time was 14 (10–18) minutes, with trifecta being achieved in 74% (n = 240) of patients. In MLR models predicting off-clamp surgery, an increasing R.E.N.A.L. score was independently associated with a lower chance of attempting such a technique (OR: 0.69, p-value < 0.001). In models predicting trifecta achievement, both a higher R.E.N.A.L. score (OR: 0.78, p-value = 0.007) and the presence of multiple lesions (OR: 0.29, p-value = 0.007) were independently associated with lower chances of reaching the outcome. Significant upstaging of chronic kidney disease (CKD) stage was recorded in 9.4% of patients after one year of follow-up. Conclusions: We reported the contemporary outcomes of patients treated with RAPN by highly experienced surgeons from two referral centers. This report represents a valid benchmark that could be used for individual patient counseling in the decision-making process.

19 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Simone MorraSimone Morra
Simone Morra
SRStefano Resca
Stefano Resca
NFNicola Frego
Nicola Frego
STSara Tamburini
Sara Tamburini
MTMarco Ticonosco
Marco Ticonosco
AMAlexandre M. Mottrie
Alexandre M. Mottrie
Background/Objectives: Robot-assisted radical cystectomy (RARC) has demonstrated improved perioperative outcomes and recovery in bladder cancer (BCa) patients. This study compares patient and tumor characteristics, operative time (OT), length of stay (LOS), and complication rates between a historical (2003–2016) and a contemporary cohort (2017–2024) treated at a high-volume robotic center. Methods: Data from 274 BCa patients who underwent RARC at AZORG Hospital, Aalst, Belgium, were analyzed. Perioperative outcomes were compared between cohorts. Multivariable Poisson regression models identified predictors of longer OT and LOS, while multivariable logistic regression models (MLRMs) assessed predictors of higher complication rates. Results: Overall, 274 BCa patients who underwent RARC were identified (38% historical cohort vs. 62% contemporary cohort). The contemporary cohort had a significantly shorter median OT (345 vs. 360 min; p = 0.048) and LOS (8 vs. 12 days; p < 0.001) compared to the historical cohort. Postoperative complications were lower in the contemporary group, with more cases experiencing no complications (60% vs. 41%) and fewer grade 3–4 complications (10% vs. 27%; p < 0.001). In multivariable Poisson regression, the contemporary cohort was an independent predictor of shorter OT (Incidence Rate Ratio [IRR]: 0.94, 95% [Confidence Interval] CI: 0.93–0.96; p = 0.04) and shorter LOS (IRR: 0.65, 95% CI: 0.60–0.69; p < 0.001). In MLRMs predicting complications, the contemporary cohort was associated with lower risk (Odds Ratio: 0.42, 95% CI: 0.23–0.76; p = 0.005). Conclusions: RARC outcomes improved significantly over time, with reduced OT, LOS, and complication rates in the contemporary cohort, highlighting advancements in surgical techniques, perioperative care, and patient safety. These findings reinforce the role of RARC in optimizing BCa treatment.

31 August 2026 in Journal of Endourology
Verified
Journal Article
Closed access
Andrea Noya-MourulloAndrea Noya-Mourullo
Andrea Noya-Mourullo
PPPietro Pasquini
Pietro Pasquini
STSara Tamburini
Sara Tamburini
FCFrancesco Cei
Francesco Cei
EBEdoardo Beatrici
Edoardo Beatrici
GNGeert De Naeyer
Geert De Naeyer
Background: Pelvic procedures with the Hugo™ RAS system maintain a stable setup with minimal variations, and upper urinary tract procedures exhibit significant variability in configurations and approaches. This review investigates the feasibility and safety of the Hugo™ RAS system in upper urinary tract procedure, analyzing the heterogeneous configuration possibilities offered by this multicart robotic platform. Methods: A systematic review was designed following the PICO framework and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search was performed in Scopus, PubMed, and Embase, covering studies up to March 12, 2025. The protocol was registered on Open Science Framework prior to data extraction: https://doi.org/10.17605/OSF.IO/T9B4Q . Results: A total of 256 articles were identified. Nineteen studies were analyzed, including 226 patients. The majority were prospective studies ( n = 10, 53%). Fourteen among the 19 studies evaluated robot-assisted partial nephrectomy, one robot-assisted radical nephrectomy (RARN), one nephroureterectomy, one adrenalectomy, and one pyeloplasty. One additional multiprocedure study reported two ureteral reimplantations, one ureteropelvic junction repair, one RARN, and one ureterolithotomy. Significant variations in robotic setup were observed: three robotic arms were used in 36.8% of the studies, while four arms in 52.6% of them. Mean operative time was 93 ± 41 minutes, docking time 7 ± 5.5 minutes, estimated blood loss 150 ± 86.15 mL, with a mean hospital stay of 3 ± 2 days. Conclusion: Hugo™ RAS appears to be an effective robotic platform for upper urinary tract procedure, with high adaptability to the surgical field.

1 November 2025 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
MAMario De Angelis
Mario De Angelis
PSPietro Scilipoti
Pietro Scilipoti
RLRiccardo Leni
Riccardo Leni
MLMattia Longoni
Mattia Longoni
PZPaolo Zaurito
Paolo Zaurito
MBMarco Bandini
Marco Bandini

26 May 2026 in Urology Video Journal
Verified
Journal Article
Open access
Andrea Noya-MourulloAndrea Noya-Mourullo
Andrea Noya-Mourullo
MAMario de Angelis
Mario de Angelis
SRStefano Resca
Stefano Resca
NFNicola Frego
Nicola Frego
STSara Tamburini
Sara Tamburini
RGRuben De Groote
Ruben De Groote